NCT05607888

Brief Summary

This observational prospective clinical study aims to describe the epidemiology, management and outcome of patients with sinonasal and skull-base pathology (tumours and diseases with malignant clinical characteristics) in a tertiary otorhinolaryngology referral centre. The main questions it aims to answer are:

  • what is the caseload of patients with the included pathology in our centre
  • what are the results of management of these cases
  • what are the epidemiological characteristics of included patients
  • what is the quality of life of included patients.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
20mo left

Started Jan 2022

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress73%
Jan 2022Dec 2027

Study Start

First participant enrolled

January 1, 2022

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

October 30, 2022

Completed
8 days until next milestone

First Posted

Study publicly available on registry

November 7, 2022

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2027

Expected
12 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

April 29, 2026

Status Verified

April 1, 2026

Enrollment Period

5 years

First QC Date

October 30, 2022

Last Update Submit

April 27, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • Absence of the disease

    Absence of the disease after the treatment has been completed

    twelve months after the treatment completion

  • Overall survival

    Survival after the treatment has been completed

    twelve months after the treatment completion

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population will be recruited from patients referred to the tertiary otorhinolaryngology referral centre. The referral applies to the in-hospital or outpatient setting.

You may qualify if:

  • sinonasal and/or skull-base cancer
  • sinonasal disease expanding through the skull-base
  • the patient's written informed consent

You may not qualify if:

  • lateral skull-base disease primarily originating in the temporal bone and without central skull-base involvement

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Medical Centre Ljubljana

Ljubljana, Ljubljana, 1000, Slovenia

RECRUITING

Related Publications (1)

  • Vozel D, Urbancic J, Battelino S, Urbancic NB, Steiner N, Felbabic T, Bosnjak R. Quality of life in Slovenian patients with skull base tumours: cross-cultural adaptation and validation of a Slovenian skull base inventory. Radiol Oncol. 2026 Jan 21;60(1):106-113. doi: 10.2478/raon-2026-0007. eCollection 2026 Mar 1.

MeSH Terms

Conditions

Nose NeoplasmsSkull Base NeoplasmsParanasal Sinus Diseases

Condition Hierarchy (Ancestors)

Skull NeoplasmsBone NeoplasmsNeoplasms by SiteNeoplasmsOtorhinolaryngologic NeoplasmsHead and Neck NeoplasmsBone DiseasesMusculoskeletal DiseasesNose DiseasesRespiratory Tract DiseasesRespiratory Tract NeoplasmsOtorhinolaryngologic Diseases

Study Officials

  • Domen Vozel, MD, PhD

    University Medical Centre Ljubljana

    STUDY DIRECTOR
  • Jure Urbančič, MD

    University Medical Centre Ljubljana

    STUDY DIRECTOR

Central Study Contacts

Domen Vozel, MD, PhD

CONTACT

Jure Urbančič, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Domen Vozel, MD, PhD, principal investigator

Study Record Dates

First Submitted

October 30, 2022

First Posted

November 7, 2022

Study Start

January 1, 2022

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

December 31, 2027

Last Updated

April 29, 2026

Record last verified: 2026-04

Locations